Related Articles
Emetic control in breast cancer patients receiving iv CMF
ONDANSETRON VERSUS METOCLOPRAMIDE IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - A METAANALYSIS
CISPLATIN-INDUCED ALTERATIONS OF SEROTONIN METABOLISM IN PATIENTS WITH OR WITHOUT EMESIS FOLLOWING CHEMOTHERAPY
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
5-HT3 ANTAGONIST ONDANSETRON FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN AN OUTPATIENT POPULATION